# Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

> **NCT00549601** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 142 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
- **DRUG:** Rivastigmine patch (9.5 mg/day)
- **DRUG:** Rivastigmine capsules (6 mg to 12 mg/day)

## Key facts

- **NCT ID:** NCT00549601
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2011-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549601, "Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00549601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*